Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Managed IT Services As A Money Saving Mechanism

Successful business owners realize the importance of reducing operating costs without affecting their company’s overall performance. Saving time and money is always a fundamental business goal, and it is more important than ever in small and midsize companies...

Gold and the Debasement of Currency Con

It is reasonably well known that many Roman emperors debased their currency (coinage). This was a very bad practice, since it is really a reflection of the debasement of the value of the kingdom (empire or country); going from a honest and just society to a corrupt and unjust ...

Market Action Suggests Downside in Precious Metals

At present, there could be a number of positive developments for precious metals. Last Friday, the US Dollar cracked lower and could be at risk of lower levels into year end. Days earlier the Federal Reserve announced new “QE-like” measures just a...

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. Global biopharmaceutical company Insmed Inc. (INSM:NASDAQ) , which is...

Investment opportunities in America's energy pipeline needs

The Keystone XL ruckus shone a light on pipelines like never before. From the heated nature of the debate one could be forgiven for thinking that long, high-volume pipelines are something new to America. Really, that couldn't be further from the truth: The United States bu...

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark

Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. This morning clinical-stage biopharmaceutical developer of medicines for th...

Top 5 Smart Contract Technology Platforms in 2019

Cryptocurrency is still the hot trend. The industry enjoyed a great boom in 2017 — then, Bitcoin skyrocketed, and so did almost all altcoins. ICOs also gained immense popularity, collecting more than $7 billion in investments . The trend was expected to continue in 2018, but ...
1 2 3 4 5 6